Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Pembrolizumab |
Indication/Tumor Type | gastric adenocarcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | gastric adenocarcinoma | sensitive | Pembrolizumab | Phase II | Actionable | In a Phase II trial (KEYNOTE-059) that supported FDA approval, Keytruda (pembrolizumab) treatment resulted in an objective response rate of 15.5% (23/148, complete response 3, partial response 20) with a median response duration of 16.3 months in patients with CD274 (PD-L1)-positive (CPS >1) gastric cancer or gastroesophageal junction adenocarcinoma (PMID: 29543932; NCT02335411). | 29543932 |
CD274 positive | gastric adenocarcinoma | sensitive | Pembrolizumab | Phase I | Actionable | In a Phase Ib trial, Keytruda (pembrolizumab) treatment resulted in partial response in 22% (8/36) of patients with CD274 (PD-L1)-positive gastric or gastroesophageal junction adenocarcinoma (PMID: 27157491). | 27157491 |
PubMed Id | Reference Title | Details |
---|---|---|
(27157491) | Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. | Full reference... |
(29543932) | Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. | Full reference... |